Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nanoscale dysregulation of collagen structure-function disrupts mechano-homeostasis and mediates pulmonary fibrosis.
Jones MG, Andriotis OG, Roberts JJ, Lunn K, Tear VJ, Cao L, Ask K, Smart DE, Bonfanti A, Johnson P, Alzetani A, Conforti F, Doherty R, Lai CY, Johnson B, Bourdakos KN, Fletcher SV, Marshall BG, Jogai S, Brereton CJ, Chee SJ, Ottensmeier CH, Sime P, Gauldie J, Kolb M, Mahajan S, Fabre A, Bhaskar A, Jarolimek W, Richeldi L, O'Reilly KM, Monk PD, Thurner PJ, Davies DE. Jones MG, et al. Among authors: monk pd. Elife. 2018 Jul 3;7:e36354. doi: 10.7554/eLife.36354. Elife. 2018. PMID: 29966587 Free PMC article.
Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial.
Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, Gabbay FJ, Davies DE, Holgate ST, Ho LP, Clark T, Djukanovic R, Wilkinson TMA; Inhaled Interferon Beta COVID-19 Study Group. Monk PD, et al. Lancet Respir Med. 2021 Feb;9(2):196-206. doi: 10.1016/S2213-2600(20)30511-7. Epub 2020 Nov 12. Lancet Respir Med. 2021. PMID: 33189161 Free PMC article. Clinical Trial.
Nebulised interferon-β1a (SNG001) in hospitalised COVID-19: SPRINTER phase III study.
Monk PD, Brookes JL, Tear VJ, Batten TN, Mankowski M, Adzic-Vukicevic T, Crooks MG, Dosanjh DPS, Kraft M, Brightling CE, Gabbay FJ, Holgate ST, Djukanovic R, Wilkinson TMA. Monk PD, et al. ERJ Open Res. 2023 Mar 27;9(2):00605-2022. doi: 10.1183/23120541.00605-2022. eCollection 2023 Mar. ERJ Open Res. 2023. PMID: 36994453 Free PMC article.
Experimental rhinovirus 16 infection in moderate asthmatics on inhaled corticosteroids.
Adura PT, Reed E, Macintyre J, Del Rosario A, Roberts J, Pestridge R, Beegan R, Boxall CB, Xiao C, Kebadze T, Aniscenko J, Cornelius V, Gern JE, Monk PD, Johnston SL, Djukanović R. Adura PT, et al. Among authors: monk pd. Eur Respir J. 2014 Apr;43(4):1186-9. doi: 10.1183/09031936.00141713. Epub 2013 Dec 5. Eur Respir J. 2014. PMID: 24311773 Free article. No abstract available.
The effect of inhaled IFN-β on worsening of asthma symptoms caused by viral infections. A randomized trial.
Djukanović R, Harrison T, Johnston SL, Gabbay F, Wark P, Thomson NC, Niven R, Singh D, Reddel HK, Davies DE, Marsden R, Boxall C, Dudley S, Plagnol V, Holgate ST, Monk P; INTERCIA Study Group. Djukanović R, et al. Am J Respir Crit Care Med. 2014 Jul 15;190(2):145-54. doi: 10.1164/rccm.201312-2235OC. Am J Respir Crit Care Med. 2014. PMID: 24937476 Free PMC article. Clinical Trial.
A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma.
Cohen ES, Dobson CL, Käck H, Wang B, Sims DA, Lloyd CO, England E, Rees DG, Guo H, Karagiannis SN, O'Brien S, Persdotter S, Ekdahl H, Butler R, Keyes F, Oakley S, Carlsson M, Briend E, Wilkinson T, Anderson IK, Monk PD, von Wachenfeldt K, Eriksson PO, Gould HJ, Vaughan TJ, May RD. Cohen ES, et al. Among authors: monk pd. MAbs. 2014 May-Jun;6(3):756-64. doi: 10.4161/mabs.28394. Epub 2014 Feb 28. MAbs. 2014. PMID: 24583620 Free PMC article.
Protein engineering and preclinical development of a GM-CSF receptor antibody for the treatment of rheumatoid arthritis.
Minter RR, Cohen ES, Wang B, Liang M, Vainshtein I, Rees G, Eghobamien L, Harrison P, Sims DA, Matthews C, Wilkinson T, Monk P, Drinkwater C, Fabri L, Nash A, McCourt M, Jermutus L, Roskos L, Anderson IK, Sleeman MA. Minter RR, et al. Br J Pharmacol. 2013 Jan;168(1):200-11. doi: 10.1111/j.1476-5381.2012.02173.x. Br J Pharmacol. 2013. PMID: 22913645 Free PMC article.
Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma.
May RD, Monk PD, Cohen ES, Manuel D, Dempsey F, Davis NH, Dodd AJ, Corkill DJ, Woods J, Joberty-Candotti C, Conroy LA, Koentgen F, Martin EC, Wilson R, Brennan N, Powell J, Anderson IK. May RD, et al. Among authors: monk pd. Br J Pharmacol. 2012 May;166(1):177-93. doi: 10.1111/j.1476-5381.2011.01659.x. Br J Pharmacol. 2012. PMID: 21895629 Free PMC article.
13 results